• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
MENG Yue, ZHANG Ziqiang, HE Shuwang, YAO Jing. Advances in research on pediatric oral liquid dosage forms[J]. Journal of China Pharmaceutical University, 2021, 52(1): 113-121. DOI: 10.11665/j.issn.1000-5048.20210116
Citation: MENG Yue, ZHANG Ziqiang, HE Shuwang, YAO Jing. Advances in research on pediatric oral liquid dosage forms[J]. Journal of China Pharmaceutical University, 2021, 52(1): 113-121. DOI: 10.11665/j.issn.1000-5048.20210116
shu

Advances in research on pediatric oral liquid dosage forms

  • 1.

    School of Pharmacy, China Pharmaceutical University, Nanjing 210009

  • 2.

    Nanjing Zeheng Pharmaceutical Technology Co., Ltd., Nanjing 210046

  • 3.

    Shandong Dayin Marine Biopharmaceutical Co., Ltd., Rongcheng 264300, China

Funds: This study was supported by China National Key Hi-Tech Innovation Project for the R&D of Novel Drugs (No.2018ZX09721003-007-005)
More Information
  • Received Date: September 16, 2020
  • Revised Date: December 03, 2020
    Graphical Abstract
    • Abstract
  • Liquid preparations are the commonly used oral dosage forms in pediatric clinical practice.This review introduces the pediatric oral liquid dosage forms including extemporaneous preparation of oral liquid formulations, oral liquid sustained and controlled release formulations, nanosuspensions, nanoemulsions, self-nanoemulsions and milk-based liquid formulations.In addition, the efficient flavoring and taste masking technologies, using safe pharmaceutical excipients, high-demanding technical standards and verification strategies, establishing excellent workflow management systems can contribute to the development and application of pediatric oral liquid dosage forms which are safer, more effective and better compliant.This review is helpful in laying the relevant theoretical foundation for further studies on pediatric oral liquid dosage forms.
    • FullText(HTML)
    • References (38)
  • [1]
    . J Chin Pharm Univ（中国药科大学学报）， 2019， 50（6）： 631-640.
    [2]
    Bruns C， Ober M. Development and preparation of oral suspensions for paediatric patients：a challenge for pharmacists［J］. Pharm Technol Hosp Pharm， 2018， 3（2）： 113-119.
    [3]
    Ip K， Shan A， Carvalho M， et al. Physicochemical stability of extemporaneously prepared oral suspension of fluconazole 50 mg/mL in SuspendltTM［J］. Pharm Technol Hosp Pharm， 2018， 3（2）： 101-112.
    [4]
    Bellay R， Bonnaure AC， Rault P， et al. Stability of 5 mg/mL nitrendipine oral suspension in Syrspend? SF PH4［J］. Pharm Technol Hosp Pharm， 2018， 3（1）： 31-37.
    [5]
    Polonini H， da Silva SL， Cunha CN， et al. Stability of azathioprine， clonidine hydrochloride， clopidogrel bisulfate， ethambutol hydrochloride， griseofulvin， hydralazine hydrochloride， nitrofurantoin， and thioguanine oral suspensions compounded with Syrspend SF PH4［J］. Int J Pharm Compd， 2020， 24（3）： 252-262.
    [6]
    Polonini H， da Silva SL， Brand?o MAF， et al. Compatibility of baclofen， carvedilol， hydrochlorothiazide， mercaptopurine， methadone hydrochloride， oseltamivir phosphate， phenobarbital， propranolol hydrochloride， pyrazinamide， sotalol hydrochloride， spironolactone， tacrolimus monohydrate， ursodeoxycholic acid， and vancomycin hydrochloride oral suspensions compounded with Syrspend SF PH4［J］. Int J Pharm Compd， 2018， 22（6）： 516-526.
    [7]
    Yang QU， Meng X， Liu D， et al. Fabrication and in vitro and in vivo evaluation of a novel bromine-resinate sustained release suspensions［J］. Latin Am J Pharm， 2018， 37（11）： 2211-2222.
    [8]
    Teresk MG， Berkland CJ， Dormer NH. Deficiencies in traditional oral dosage forms and the emergence of controlled- release powder manufacturing［J］. Kona Powder Part J， 2017， 34： 91-105.
    [9]
    Oz UC， Devrim B， Bozk?r A， et al. Development of reconstitutable suspensions containing diclofenac sodium-loaded microspheres for pediatric delivery［J］. J Microencapsul， 2015， 32（4）： 317-328.
    [10]
    Rauf A， Kanwal U， Bukhari NI， et al. Development and characterization of taste masked ampicillin microspheres for pediatric oral use［J］. Latin Am J Pharm， 2018， 37（2）： 321-329.
    [11]
    Cirri M， Mennini N， Maestrelli F， et al. Development and in vivo evaluation of an innovative “Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles” formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics［J］. Int J Pharm， 2017， 521（1/2）： 73-83.
    [12]
    Cirri M， Maestrelli F， Mura P， et al. Combined approach of cyclodextrin complexation and nanostructured lipid carriers for the development of a pediatric liquid oral dosage form of hydrochlorothiazide［J］. Pharmaceutics， 2018， 10（4）： 287.
    [13]
    Cirri M， Maestrini L， Maestrelli F， et al. Design， characterization and in vivo evaluation of nanostructured lipid carriers （NLC） as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy［J］. Drug Deliv， 2018， 25（1）： 1910-1921.
    [14]
    Aher SS， Malsane ST， Saudagar RB. Nanosuspension： an overview［J］. Int J Curr Pharm Res， 2017， 9（3）： 19-23.
    [15]
    Gonzalez MA， Ramírez Rigo MV， Gonzalez Vidal NL. Orphan formulations in pediatric schistosomiasis treatment： development and characterization of praziquantel nanoparticle-loaded powders for reconstitution［J］. AAPS PharmSciTech， 2019， 20（8）： 318.
    [16]
    Manyarara TE， Star K， Admire D， et al. Formulation and characterization of a paediatric nanoemulsion dosage form with modified oral drug delivery system for improved dissolution rate of nevirapine［J］. Mrs Adv， 2018， 3（37）： 2203-2219.
    [17]
    Halicki PCB， H?drich G， Boschero R， et al. Alternative pharmaceutical formulation for oral administration of rifampicin［J］. Assay Drug Dev Technol， 2018， 16（8）： 456-461.
    [18]
    Dai Q， Zhang P， Jin Y， et al. Using self-nanoemulsifying system to improve oral bioavailability of a pediatric antiepileptic agent stiripentol： formulation and pharmacokinetics studies［J］. AAPS PharmSciTech， 2020， 21（5）： 192.
    [19]
    Abouhussein DMN， Mahmoud D BED， Mohammad FE. Design of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and emergency cases［J］. J Liposome Res， 2019， 29（4）： 399-412.
    [20]
    Soulele K， Macheras P. Milk as a medium for pediatric formulations： experimental findings and regulatory aspects［J］. Int J Pharm， 2015， 492（1/2）： 344-345.
    [21]
    Boyd BJ， Salim M， Clulow AJ， et al. The impact of digestion is essential to the understanding of milk as a drug delivery system for poorly water soluble drugs［J］. J Control Release， 2018， 292： 13-17.
    [22]
    Gerrard SE， Orlu-Gul M， Tuleu C， et al. Modeling the physiological factors that affect drug delivery from a nipple shield delivery system to breastfeeding infants［J］. J Pharm Sci， 2013， 102（10）： 3773-3783.
    [23]
    Flynn AD， Scheuerle RL， Galgon G， et al. Community feedback on the JustMilk Nipple Shield Delivery System in the Vhembe District of Limpopo Province， South Africa［J］. South Afr J Child Health， 2017， 11（4）： 192-197.
    [24]
    Lopez FL， Ernest TB， Tuleu C， et al. Formulation approaches to pediatric oral drug delivery： benefits and limitations of current platforms［J］. Expert Opin Drug Deliv， 2015， 12（11）： 1727-1740.
    [25]
    Rajabalaya R， Musa MN， Kifli N， et al. Oral and transdermal drug delivery systems： role of lipid-based lyotropic liquid crystals［J］. Drug Des Devel Ther， 2017， 11： 393-406.
    [26]
    Fan YL， Chen H， Huang ZW， et al. Taste-masking and colloidal-stable cubosomes loaded with cefpodoxime proxetil for pediatric oral delivery［J］. Int J Pharm， 2020， 575： 118875.
    [27]
    Petrovick GF， Breitkreutz J， Pein-Hackelbusch M. Taste-masking properties of solid lipid based micropellets obtained by cold extrusion-spheronization［J］. Int J Pharm， 2016， 506（1/2）： 361-370.
    [28]
    Shen L， Zhang YD， Zhang JL， et al. Reversed lipid-based nanoparticles dispersed in iodized oil for transarterial chemoembolization［J］. ACS Appl Mater Interfaces， 2019， 11（23）： 20642-20648.
    [29]
    Zhang YD， Shen L， Wang T， et al. Taste masking of water-soluble drug by solid lipid microspheres： a child-friendly system established by reversed lipid-based nanoparticle technique［J］. J Pharm Pharmacol， 2020， 72（6）： 776-786.
    [30]
    Omar SM， Ibrahim F， Ismail A. Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste［J］. Saudi Pharm J， 2020， 28（3）： 349-361.
    [31]
    Hijazi Vega M， Cavada-Carranza I， Hernán-Moreno N， et al. 5PSQ-097 Potentially harmful excipients in neonatal and paediatric patients［J］. Eur J Hosp Pharm，， 2020， 27： A194.
    [32]
    Binson G， Beuzit K， Migeot V， et al. Preparation and physicochemical stability of liquid oral dosage forms free of potentially harmful excipient designed for pediatric patients［J］. Pharmaceutics， 2019， 11（4）： 190.
    [33]
    Barbosa R， Capela A， Sampaio C， et al. 3PC-028 Compounding an oral liquid formulation of diazepam alcohol free［J］. Eur J Hosp Pharm， 2020， 27： A34-A35.
    [34]
    Valeur KS， Hertel SA， Lundstr?m KE， et al. Safe excipient exposure in neonates and small children - protocol for the SEEN project［J］. Dan Med J， 2017， 64（2）： A5324.
    [35]
    Engels MJ， Ciarkowski SL， Rood J， et al. Standardization of compounded oral liquids for pediatric patients in Michigan［J］. Am J Health Syst Pharm， 2016， 73（13）： 981-990.
    [36]
    Suárez-González J， Santove?a-Estévez A， Armijo-Ruíz S， et al. A high-demanding strategy to ensure the highest quality standards of oral liquid individualized medicines for pediatric use［J］. AAPS PharmSciTech， 2019， 20（5）： 208.
    [37]
    Davis SJ， Hurtado J， Nguyen R， et al. Innovations in medication preparation safety and wastage reduction： use of a workflow management system in a pediatric hospital［J］. Hosp Pharm， 2017， 52（1）： 54-59.
    [38]
    Bledsoe S， Van Buskirk A， Falconer RJ， et al. Errors detected in pediatric oral liquid medication doses prepared in an automated workflow management system［J］. Am J Health Syst Pharm， 2018， 75（3）： 127-131.
    • Related Articles

  • Related Articles

    [1]XIA Ying, GUO Hongli, HU Yahui, CHEN Feng. Therapeutic drug monitoring for monoclonal antibody：progress in the application of LC-MS/MS technique[J]. Journal of China Pharmaceutical University, 2021, 52(1): 122-128. DOI: 10.11665/j.issn.1000-5048.20210117
    [2]JI Shunli, SONG Fanfan, ZHENG Yang, DING Li. Simultaneous determination of amoxicillin and clavulanic acid by LC-MS/MS in human plasma and its application to a bioequivalence study[J]. Journal of China Pharmaceutical University, 2019, 50(6): 699-706. DOI: 10.11665/j.issn.1000-5048.20190610
    [3]LIANG Feng, LI Duo, WANG Rongbin, SHU Chang, DING Li. Pharmacokinetics and absolute bioavailability of isoschaftoside in rat by LC-MS/MS[J]. Journal of China Pharmaceutical University, 2019, 50(1): 75-80. DOI: 10.11665/j.issn.1000-5048.20190110
    [4]LIU Chaoyi, ZHANG Ge, HANG Taijun, WANG Lei, ZHANG Xiaofei, SONG Min. Identification of related substances in rivaroxaban by LC-MS[J]. Journal of China Pharmaceutical University, 2015, 46(4): 450-457. DOI: 10.11665/j.issn.1000-5048.20150411
    [5]LI Jingjing, TAN Jingfu, YANG Jie, WANG Qiang. Pharmacokinetic study of corosolic acid in normal rats and diabetic rats by LC-MS[J]. Journal of China Pharmaceutical University, 2014, 45(1): 84-87. DOI: 10.11665/j.issn.1000-5048.20140115
    [6]YANG Youtian, MAO Baiyang, CHENG Lifei, SU Mengxiang, DI Bin. Identification of the related substances in telmisartan/amlodipine double layer tablets by LC-MS/MS[J]. Journal of China Pharmaceutical University, 2014, 45(1): 65-69. DOI: 10.11665/j.issn.1000-5048.20140111
    [7]MU Yanan, YANG Jin. Determination of epothilone B in human blood by LC-MS/MS and its application in phase I pharmacokinetics study[J]. Journal of China Pharmaceutical University, 2013, 44(1): 89-92. DOI: 10.11665/j.issn.1000-5048.20130115
    [8]SI Qian, CHEN Yuan-cheng, HUANG Li-hua, CHENG Yu, HE Hua, LIU Xiao-quan. Determination of nebivolol in human plasma by LC-MS/MS and study of its pharmacokinetics on the Chinese[J]. Journal of China Pharmaceutical University, 2011, 42(2): 136-140.
    [9]Determination of Ranolazine and Its Pharmacokinetics in Dog by LC-MS[J]. Journal of China Pharmaceutical University, 2004, (2): 59-62.
    [10]Determination of Clarithromycin in Human Plasma by LC-MS Method[J]. Journal of China Pharmaceutical University, 2004, (1): 52-55.

Catalog

    Get Citation
    PDF
    XML
    Article views (374) PDF downloads (1113) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：304015

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return